Breaking News

Pfizer Expands Rare Disease R&D

Will collaborate with Spark to progress SPK-FIX clinical program in hemophilia B

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer is expanding its rare disease R&D activities through the establishment of a gene therapy platform to investigate potential treatments. Under an agreement with Spark Therapeutics, the companies will collaborate to progress the clinical program for SPK-FIX, a program incorporating a bio-engineered AAV vector for the potential treatment of hemophilia B, which is expected to enter Phase 1/2 trials in 1H15.   Spark will be responsible for clinical development through Phase 1/2 studies. Pfi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters